当前位置： SCI文献检索 > Molecular Oncology期刊下所有文献 > Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.

Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma.

Abstract：

:Protein inhibitor of activated STAT3 (PIAS3) is an endogenous suppressor of signal transducer and activator of transcription 3 (STAT3) signaling. By directly interacting with phosphorylated STAT3, PIAS3 can block the downstream transcriptional activity of STAT3, which is hyper-activated in various cancers. We previously reported that in malignant mesothelioma (MM), low PIAS3 expression is associated with increased STAT3 activation and correlates with poor patient survival, yet the regulatory mechanism(s) governing PIAS3 expression in MM remain unclear. Here, we demonstrate that PIAS3 protein expression does not correlate with its mRNA level in MM cell lines, indicating that PIAS3 expression is regulated at a post-transcriptional level. Inhibition of proteasomal degradation with MG132 (10 μm) or bortezomib (1 μm), alone and in combination, did not increase PIAS3 protein levels; furthermore, inhibition of protein synthesis by cycloheximide treatment did not decrease PIAS3 levels within 48 h, suggesting that PIAS3 expression is not actively regulated at a post-translational level. To determine whether miRNA (miRs) can translationally regulate PIAS3 expression, we combined miR microarray analysis with bioinformatic screening to identify candidate miRs, in MM cell lines with low PIAS3 expression, followed by luciferase reporter assays to validate miR regulation of the PIAS3 3'UTR. We identified miR-18a as a suppressor of PIAS3 expression that is upregulated in MM cells and whose inhibition can increase PIAS3 expression and suppress STAT3 activity. Moreover, we showed that miR-18a inhibition can decrease MM cell viability and that its expression is negatively correlated with MM patient survival. Taken together, these results suggest that targeting miR-18a may have therapeutic benefit in MM.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

He T,McColl K,Sakre N,Chen Y,Wildey G,Dowlati A

doi

10.1002/1878-0261.12386

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

2124-2135

issue

12

eissn

1574-7891

issn

1878-0261

journal_volume

12

pub_type

杂志文章

相关文献

Molecular Oncology文献大全
  • Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

    abstract：:The presence of circulating tumor cells (CTCs) in the blood of ovarian cancer patients was shown to correlate with decreased overall survival, whereby CTCs with epithelial-mesenchymal-transition (EMT) or stem-like traits are supposed to be involved in metastatic progression and recurrence. Thus, investigating the tran...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.04.002

    authors： Blassl C,Kuhlmann JD,Webers A,Wimberger P,Fehm T,Neubauer H

    更新日期：2016-08-01 00:00:00

  • The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.

    abstract：:The abnormal expression of long noncoding RNAs (lncRNAs) is associated with human carcinoma. The present study aimed to investigate the mechanisms underlying the function of lncRNA AK002107 in the progression of hepatocellular carcinoma (HCC). The differential expression of lncRNAs between HCC and paired nontumor tiss...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12487

    authors： Tang YH,He GL,Huang SZ,Zhong KB,Liao H,Cai L,Gao Y,Peng ZW,Fu SJ

    更新日期：2019-05-01 00:00:00

  • Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.

    abstract：:Gene and protein expression of programmed death-ligand 1 (PD-L1) are prognostic in early breast cancer (BC), but their prognostic information is inconsistent at least in some biological subgroups. The validated prognostic gene signatures (GS) in BC are mainly based on proliferation and estrogen receptor (ER)-related g...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12654

    authors： Zerdes I,Sifakis EG,Matikas A,Chrétien S,Tobin NP,Hartman J,Rassidakis GZ,Bergh J,Foukakis T

    更新日期：2020-05-01 00:00:00

  • Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.

    abstract：:Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called 'liquid biopsy' can be applied to monitor response...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.12.005

    authors： Siravegna G,Bardelli A

    更新日期：2016-03-01 00:00:00

  • Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

    abstract：BACKGROUND:DNA methylation alterations are early events in tumorigenesis and important in the regulation of gene expression in cancer cells. Lung cancer patients have in general a poor prognosis, and a deeper insight into the epigenetic landscape in lung adenocarcinoma tumors and its prognostic implications is needed. ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.10.021

    authors： Bjaanæs MM,Fleischer T,Halvorsen AR,Daunay A,Busato F,Solberg S,Jørgensen L,Kure E,Edvardsen H,Børresen-Dale AL,Brustugun OT,Tost J,Kristensen V,Helland Å

    更新日期：2016-02-01 00:00:00

  • The metastasis-associated molecule C4.4A promotes tissue invasion and anchorage independence by associating with the alpha6beta4 integrin.

    abstract：:C4.4A is a metastasis-associated molecule that functions appear to rely on associated alph6beta4 integrin. To corroborate the impact of the C4.4A-alpha6beta4 integrin association on metastasis formation, C4.4A was knocked-down in a highly metastatic rat pancreatic adenocarcinoma (ASML, ASML-C4.4Akd). Metastasis format...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2013.05.002

    authors： Thuma F,Ngora H,Zöller M

    更新日期：2013-10-01 00:00:00

  • Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.

    abstract：:Glycosylation is the stepwise procedure of covalent attachment of oligosaccharide chains to proteins or lipids, and alterations in this process have been associated with malignant transformation. Simultaneous analysis of the expression of all glycan-related genes clearly gives the advantage of enabling a comprehensive...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2009.12.001

    authors： Potapenko IO,Haakensen VD,Lüders T,Helland A,Bukholm I,Sørlie T,Kristensen VN,Lingjaerde OC,Børresen-Dale AL

    更新日期：2010-04-01 00:00:00

  • Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.

    abstract：:Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton-interfering pharmacophores, in testicular germ cell tumors (T...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12582

    authors： Steinemann G,Dittmer A,Schmidt J,Josuttis D,Fähling M,Biersack B,Beindorff N,Jolante Koziolek E,Schobert R,Brenner W,Müller T,Nitzsche B,Höpfner M

    更新日期：2019-12-01 00:00:00

  • Altered JS-2 expression in colorectal cancers and its clinical pathological relevance.

    abstract：:JS-2 is a novel gene located at 5p15.2 and originally detected in primary oesophageal cancer. There is no study on the role of JS-2 in colorectal cancer. The aim of this study is to determine the gene copy number and expression of JS-2 in a large cohort of patients with colorectal tumours and correlate these to the cl...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2011.06.003

    authors： Lam AK,Gopalan V,Nassiri MR,Kasim K,Dissanayake J,Tang JC,Smith RA

    更新日期：2011-10-01 00:00:00

  • Challenges in circulating tumor cell detection by the CellSearch system.

    abstract：:Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method d...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.12.002

    authors： Andree KC,van Dalum G,Terstappen LW

    更新日期：2016-03-01 00:00:00

  • Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.

    abstract：:Hydrophobic neoantigens are more immunogenic because they are better presented by the major histocompatibility complex and better recognized by T cells. Tumor cells can evade the immune response by expressing checkpoints such as programmed death ligand 1. Checkpoint blockade reactivates immune recognition and can be e...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12748

    authors： Pham TV,Boichard A,Goodman A,Riviere P,Yeerna H,Tamayo P,Kurzrock R

    更新日期：2020-08-01 00:00:00

  • Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

    abstract：PURPOSE:Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). We sought to characterize the transcriptomic features of LCIS and ILC, with a focus on the identification of intrinsic molecular subtypes of LCIS and the changes involved in the progression ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.12.005

    authors： Andrade VP,Morrogh M,Qin LX,Olvera N,Giri D,Muhsen S,Sakr RA,Schizas M,Ng CK,Arroyo CD,Brogi E,Viale A,Morrow M,Reis-Filho JS,King TA

    更新日期：2015-04-01 00:00:00

  • Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.

    abstract：:Natural products remain a significant source of anticancer chemotherapeutics. The search for targeted drugs for cancer treatment includes consideration of natural products, which may provide new opportunities for antitumor cytotoxicity as single agents or in combination therapy. We examined the association of molecula...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12849

    authors： Krushkal J,Negi S,Yee LM,Evans JR,Grkovic T,Palmisano A,Fang J,Sankaran H,McShane LM,Zhao Y,O'Keefe BR

    更新日期：2020-11-09 00:00:00

  • Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.

    abstract：:The identification of novel antimetastatic therapeutic targets is necessary for improved treatment of patients with acquired BRAF inhibitor-resistant (BRAFi-R) melanoma, in whom metastasis is a major concern. Our present study focused on the identification of such targets to explore novel antimetastatic therapeutic op...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12433

    authors： Mohapatra P,Prasad CP,Andersson T

    更新日期：2019-02-01 00:00:00

  • miRNAs as radio-response biomarkers for breast cancer stem cells.

    abstract：:In breast cancer (BC), the presence of cancer stem cells (CSCs) has been related to relapse, metastasis, and radioresistance. Radiotherapy (RT) is an extended BC treatment, but is not always effective. CSCs have several mechanisms of radioresistance in place, and some miRNAs are involved in the cellular response to io...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12635

    authors： Griñán-Lisón C,Olivares-Urbano MA,Jiménez G,López-Ruiz E,Del Val C,Morata-Tarifa C,Entrena JM,González-Ramírez AR,Boulaiz H,Zurita Herrera M,Núñez MI,Marchal JA

    更新日期：2020-03-01 00:00:00

  • A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial-mesenchymal transition.

    abstract：:As a critical feature of the tumor microenvironment, hypoxia is known to be a potent inducer of tumor metastasis, and it has been proposed that the initial steps in metastasis involve epithelial-mesenchymal transition (EMT). The strong correlation among hypoxia, EMT, and metastasis suggests that integrative assessment...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12491

    authors： Chen YL,Zhang Y,Wang J,Chen N,Fang W,Zhong J,Liu Y,Qin R,Yu X,Sun Z,Gao F

    更新日期：2019-07-01 00:00:00

  • Genetic susceptibility to breast cancer.

    abstract：:Genetic and lifestyle/environmental factors are implicated in the aetiology of breast cancer. This review summarizes the current state of knowledge on rare high penetrance mutations, as well as moderate and low-penetrance genetic variants implicated in breast cancer aetiology. We summarize recent discoveries from larg...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2010.04.011

    authors： Mavaddat N,Antoniou AC,Easton DF,Garcia-Closas M

    更新日期：2010-06-01 00:00:00

  • MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β receptor I ubiquitination.

    abstract：:SMURF2 is a member of the HECT family of E3 ubiquitin ligases that have important roles as a negative regulator of transforming growth factor-β (TGF-β) signaling through ubiquitin-mediated degradation of TGF-β receptor I. However, the regulatory mechanism of SMURF2 is largely unknown. In this study, we identified that...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12581

    authors： Chae DK,Park J,Cho M,Ban E,Jang M,Yoo YS,Kim EE,Baik JH,Song EJ

    更新日期：2019-12-01 00:00:00

  • EVI1 splice variants modulate functional responses in ovarian cancer cells.

    abstract：:Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2013.02.008

    authors： Dutta P,Bui T,Bauckman KA,Keyomarsi K,Mills GB,Nanjundan M

    更新日期：2013-06-01 00:00:00

  • APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

    abstract：:Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12138

    authors： Shah F,Goossens E,Atallah NM,Grimard M,Kelley MR,Fishel ML

    更新日期：2017-12-01 00:00:00

  • Near infrared photoimmunotherapy of B-cell lymphoma.

    abstract：:Near infrared photoimmunotherapy (NIR-PIT) is a new, highly-selective cancer theranostics that employs an antibody-photo absorber conjugate (APC). NIR-PIT has successfully treated preclinical tumor models with APCs and is now in the first-in-human phase 1 clinical trial for head and neck cancer patients against EGFR. ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.07.010

    authors： Nagaya T,Nakamura Y,Sato K,Harada T,Choyke PL,Kobayashi H

    更新日期：2016-11-01 00:00:00

  • SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.

    abstract：:In our previous study, we identified 1241 loci with somatic copy number alterations in human hepatocellular carcinoma (HCC) using Affymetrix SNP 6.0 arrays, and a putative cancer gene SERPINA5 was uncovered in a novel chromosomal region with recurrent copy number loss at 14q31.1-32.13. The SERPINA5 was reported to be ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2013.12.003

    authors： Jing Y,Jia D,Wong CM,Oi-Lin Ng I,Zhang Z,Liu L,Wang Q,Zhao F,Li J,Yao M,Wu X,He X

    更新日期：2014-03-01 00:00:00

  • Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

    abstract：:CDC25 (cell division cycle 25) phosphatases are essential for cell cycle control under normal conditions and in response to DNA damage. They are represented by three isoforms, CDC25A, B and C, each of them being submitted to an alternative splicing mechanism. Alternative splicing of many genes is affected in response ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2012.06.003

    authors： Albert H,Battaglia E,Monteiro C,Bagrel D

    更新日期：2012-10-01 00:00:00

  • STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.

    abstract：:The interferon-inducible transcription factor STAT1 is a tumor suppressor in various malignancies. We investigated sex-specific STAT1 functions in colitis and colitis-associated colorectal cancer (CRC) using mice with specific STAT1 deletion in intestinal epithelial cells (STAT1∆IEC ). Male but not female STAT1∆IEC mi...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12178

    authors： Crnčec I,Modak M,Gordziel C,Svinka J,Scharf I,Moritsch S,Pathria P,Schlederer M,Kenner L,Timelthaler G,Müller M,Strobl B,Casanova E,Bayer E,Mohr T,Stöckl J,Friedrich K,Eferl R

    更新日期：2018-04-01 00:00:00

  • DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.

    abstract：:The diversity of breast cancers reflects variations in underlying biology and affects the clinical implications for patients. Gene expression studies have identified five major subtypes- Luminal A, Luminal B, basal-like, ErbB2+ and Normal-Like. We set out to determine the role of DNA methylation in subtypes by perform...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.11.002

    authors： Kamalakaran S,Varadan V,Giercksky Russnes HE,Levy D,Kendall J,Janevski A,Riggs M,Banerjee N,Synnestvedt M,Schlichting E,Kåresen R,Shama Prasada K,Rotti H,Rao R,Rao L,Eric Tang MH,Satyamoorthy K,Lucito R,Wigler M,Dim

    更新日期：2011-02-01 00:00:00

  • Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

    abstract：:The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient (inter-patient heterogeneity), and within an individual (intra-patient heterogeneity) as demon...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2014.09.011

    authors： Catenacci DV

    更新日期：2015-05-01 00:00:00

  • Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

    abstract：:Pharmacogenomics is the study of genetic factors determining drug response or toxicity. The use of pharmacogenomics is especially desirable in oncology because the therapeutic index of oncology drugs is often narrow, the need for favorable drug response is often acute, and the consequences of drug toxicity can be life...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2012.01.005

    authors： O'Donnell PH,Ratain MJ

    更新日期：2012-04-01 00:00:00

  • TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells.

    abstract：:Transient receptor potential melastatin-4 channel (TRPM4) dysregulation contributes to heart conditions, immune diseases, and cervical and prostate cancer. Up to now, the involvement of TRPM4 in colorectal cancer (CRC) pathophysiology remains unknown. Here, we investigated tumor tissue microarrays from 379 CRC patient...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12566

    authors： Kappel S,Stokłosa P,Hauert B,Ross-Kaschitza D,Borgström A,Baur R,Galván JA,Zlobec I,Peinelt C

    更新日期：2019-11-01 00:00:00

  • Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study.

    abstract：:Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single-cell molecular analysis is required. We developed the ChimeraX® -i120 platform to facilitate negative enrichment, immunofluorescent labelin...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12876

    authors： Wang PX,Sun YF,Jin WX,Cheng JW,Peng HX,Xu Y,Zhou KQ,Chen LM,Huang K,Wu SY,Hu B,Zhang ZF,Guo W,Cao Y,Zhou J,Fan J,Yang XR

    更新日期：2020-12-10 00:00:00

  • Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.

    abstract：PURPOSE:To compare the distribution and prognostic effect of the breast cancer molecular subtypes in young and elderly breast cancer patients. PATIENTS AND METHODS:Our study population (n = 822) consisted of all early breast cancer patients primarily treated with surgery in our center between 1985 and 1996. A total of...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.03.022

    authors： de Kruijf EM,Bastiaannet E,Rubertá F,de Craen AJ,Kuppen PJ,Smit VT,van de Velde CJ,Liefers GJ

    更新日期：2014-07-01 00:00:00